Levocomp (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine by central aromatic L‑amino acid decarboxylase. Carbidopa, which does not cross the barrier, blocks the same enzyme in peripheral tissues, limiting peripheral conversion and increasing the amount of levodopa that reaches the brain for dopamine synthesis.

The dose of Levocomp is individualized. A qualified prescriber determines the appropriate starting dose and titration schedule based on the patient’s clinical condition, age, response and tolerability. No fixed regimen is provided here; dosing must follow the prescribing information and the clinician’s judgment.

Safety data for Levocomp in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a healthcare professional is essential.

To request Levocomp, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Levocomp (levodopa/carbidopa) directly replaces dopamine, offering the most potent symptomatic relief for motor symptoms. Dopamine agonists, such as ropinirole or pramipexole, stimulate dopamine receptors but generally provide less robust control. Levocomp is often preferred for advanced disease, while agonists may be used earlier to delay levodopa‑related motor complications.

Levocomp should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Levocomp is taken orally, usually with a small amount of food to reduce nausea. Tablets should be swallowed whole with a full glass of water and not crushed or chewed, unless the prescriber advises otherwise. Dosing times are typically spaced throughout the day to maintain steady plasma levels.

Serious adverse reactions include dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, cardiac arrhythmias, and the rare neuroleptic malignant syndrome. Patients should be monitored closely for these events, and any sudden or severe symptoms should prompt immediate medical evaluation.

Levocomp is contraindicated in patients with known hypersensitivity to levodopa, carbidopa or any excipients, and in those taking non‑selective MAO inhibitors. Caution is advised for individuals with narrow‑angle glaucoma, severe cardiovascular disease, or a history of neuroleptic malignant syndrome. The prescriber should assess each patient’s medical history before initiating therapy.